Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report.

Four Lykos Therapeutics board members have stepped down and another departed last month, the aftermath of a stalemate over ...

Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...

Private investment firm Bridgewest is combing its Australia-based biologics CDMO BioCina and its sterile injectable ...

The top three pharmacy benefit managers hiked the prices of dozens of 'specialty' generic drugs, some by more than 1000% of ...

Pfizer CEO Bourla outlines company's path forward with new R&D focus, board changes & strategy after meeting Trump, while ...

IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.

IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.

XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...

Former FDA Commissioner Scott Gottlieb said Robert F. Kennedy Jr. should not lead the US health agencies, underscoring the ...

Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle ...

The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower ...